journal article·2025-12Open access

NIR‐II Responsive Multifunctional Scaffold Enabling “Kill‐Modulation‐Build” Synergistic Therapy for Infectious Bone Defects

Qifei Yang, Shu Lou, Yuan Zhang, Zhurun Fang, Changyue Xing, Wentao Wang, Minxuan Han, Zhendong Wang, Ben Zhong Tang, Ming Zhang

Advanced Science· Volume 12· Issue 47

Abstract

Abstract Infectious bone defects present dual challenges: eliminating bacteria and regenerating tissue, which are further complicated by biofilm formation, antibiotic resistance, and chronic inflammation. Here, a near‐infrared‐II (NIR‐II) responsive fibrous scaffold (AIE NPs@BP NSs@FSs) that employs a sequential “Kill–Modulation–Build” therapeutic strategy—referring to infection clearance, immune regulation, and bone repair is developed. Upon NIR‐II irradiation, aggregation‐induced emission nanoparticles (AIE NPs) produce localized hyperthermia, which eliminates bacteria and biofilms, offering a non‐antibiotic solution that reduces the risk of resistance development. Moreover, black phosphorus nanosheets (BP NSs) scavenge reactive oxygen species (ROS) and reprogram macrophages toward a pro‐regenerative M2 phenotype. This immunomodulatory shift enhances endothelial migration, neovascularization, and osteogenic differentiation of bone marrow stem cells. With excellent biocompatibility and biomimetic architecture, the scaffold supports coordinated antibacterial, immunoregulatory, and osteoinductive responses. This work provides a promising platform for treating complex infected bone defects by combining photothermal therapy with immune and regenerative modulation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Orthopedic Infections and Treatments · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Affiliated Stomatological Hospital of Nanjing Medical University. State Key Laboratory Cultivation Base of Research Prevention and Treatment for Oral Diseases. Jiangsu Province Engineering Research Center of Stomatological Translational Medicine Nanjing Medical University Nanjing 210029 China

College of Science Nanjing Forestry University Nanjing 210037 China

School of Science and Engineering Shenzhen Institute of Aggregate Science and Technology The Chinese University of Hong Kong Shenzhen 518172 China

References (68)

Show source-provided references
1. 10.1038/s41579-022-00686-010.1038/s41579-022-00686-0 ↗
2. 10.1128/CMR.00084-1710.1128/CMR.00084-17 ↗
3. Zhang S. · Innovation. · 2023 · 4
4. 10.1002/adma.20231289710.1002/adma.202312897 ↗
5. 10.1002/adma.20230784610.1002/adma.202307846 ↗
6. 10.1016/j.bioactmat.2023.05.01410.1016/j.bioactmat.2023.05.014 ↗
7. 10.1002/adma.20230433310.1002/adma.202304333 ↗
8. Wang J. · Adv. Funct. Mater. · 2024 · 34 · 8
9. 10.1146/annurev-pathmechdis-012418-01271810.1146/annurev-pathmechdis-012418-012718 ↗
10. 10.1002/adma.20220204410.1002/adma.202202044 ↗
11. 10.1002/adma.20241518910.1002/adma.202415189 ↗
12. 10.1039/D1CS00647A10.1039/D1CS00647A ↗
13. 10.1021/acs.chemrev.3c0032610.1021/acs.chemrev.3c00326 ↗
14. 10.1039/D0CS00173B10.1039/D0CS00173B ↗
15. 10.1039/D1CS00074H10.1039/D1CS00074H ↗
16. 10.1002/adma.20200807110.1002/adma.202008071 ↗
17. Mei J. · Chem. Rev. · 2021 · 121 · 4895
18. 10.1021/acsnano.3c0805410.1021/acsnano.3c08054 ↗
19. Wang H. · Adv. Mater. · 2021 · 33
20. 10.1002/adma.20210011310.1002/adma.202100113 ↗
21. 10.1002/anie.20221333610.1002/anie.202213336 ↗
22. 10.1002/adma.20231099910.1002/adma.202310999 ↗
23. 10.1021/acsnano.2c1148610.1021/acsnano.2c11486 ↗
24. 10.1002/adma.20200338210.1002/adma.202003382 ↗
25. 10.1002/adma.20241873110.1002/adma.202418731 ↗
26. 10.1038/s41467-020-16513-010.1038/s41467-020-16513-0 ↗
27. 10.1002/advs.20240915510.1002/advs.202409155 ↗
28. 10.1002/advs.20220073210.1002/advs.202200732 ↗
29. 10.1002/adma.20240036610.1002/adma.202400366 ↗
30. 10.1021/acsnano.3c1240310.1021/acsnano.3c12403 ↗
31. 10.1002/adma.20240126410.1002/adma.202401264 ↗
32. 10.1002/adma.20231292010.1002/adma.202312920 ↗
33. 10.1038/s41565-021-00976-310.1038/s41565-021-00976-3 ↗
34. 10.1002/adma.20250016210.1002/adma.202500162 ↗
35. 10.1007/s40820-022-00937-y10.1007/s40820-022-00937-y ↗
36. Li L. · Adv. Mater. · 2020 · 32
37. 10.1002/adfm.20231237410.1002/adfm.202312374 ↗
38. 10.1002/adma.20230778510.1002/adma.202307785 ↗
39. 10.1016/j.bioactmat.2021.09.01610.1016/j.bioactmat.2021.09.016 ↗
40. 10.1038/s41467-025-57499-x10.1038/s41467-025-57499-x ↗
41. 10.1002/advs.20230482410.1002/advs.202304824 ↗
42. 10.1002/adfm.20231642810.1002/adfm.202316428 ↗
43. 10.1016/j.nantod.2022.10144710.1016/j.nantod.2022.101447 ↗
44. 10.1002/adma.20241659010.1002/adma.202416590 ↗
45. 10.1002/adma.20200272310.1002/adma.202002723 ↗
46. 10.1039/D4CS00404C10.1039/D4CS00404C ↗
47. 10.1002/adma.20241554310.1002/adma.202415543 ↗
48. 10.1038/s41573-023-00791-610.1038/s41573-023-00791-6 ↗
49. 10.1038/s41467-023-41608-910.1038/s41467-023-41608-9 ↗
50. 10.1038/s41423-020-00541-310.1038/s41423-020-00541-3 ↗
51. Xie L. · Innovation. · 2021 · 2
52. 10.1002/adma.20200417210.1002/adma.202004172 ↗
53. 10.1002/adma.20210513610.1002/adma.202105136 ↗
54. 10.1002/adma.20241920910.1002/adma.202419209 ↗
55. 10.1161/CIRCULATIONAHA.121.05407110.1161/CIRCULATIONAHA.121.054071 ↗
56. 10.1038/s41584-021-00682-310.1038/s41584-021-00682-3 ↗
57. 10.1038/s41590-020-0764-810.1038/s41590-020-0764-8 ↗
58. 10.1038/s41577-023-00848-y10.1038/s41577-023-00848-y ↗
59. 10.1002/adma.20200514010.1002/adma.202005140 ↗
60. 10.1126/sciimmunol.add196710.1126/sciimmunol.add1967 ↗
61. 10.1002/adma.20240162010.1002/adma.202401620 ↗
62. 10.1002/adma.20240801610.1002/adma.202408016 ↗
63. 10.1002/advs.20241734610.1002/advs.202417346 ↗
64. 10.1002/adma.20210015010.1002/adma.202100150 ↗
65. 10.1021/acsnano.0c0148610.1021/acsnano.0c01486 ↗
66. 10.1186/s40779-023-00454-y10.1186/s40779-023-00454-y ↗
67. 10.1002/advs.20220453510.1002/advs.202204535 ↗
68. 10.1002/advs.20240997910.1002/advs.202409979 ↗